Background The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment. Methods We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive. Results The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (≤4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors. Conclusions Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.
Carcinoma small cell Prognosis Superior vena cava syndrome
This is a preview of subscription content, log in to check access.
Gonlugur TE, Gonlugur U. Comorbidity as a prognostic factor in small cell lung cancer. Tumori. 2006;92:423–8.PubMedGoogle Scholar
Tas F, et al. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol. 1999;38:1011–5.CrossRefPubMedGoogle Scholar
The World Health Organization. The World Health Organization histological typing of lung tumors. Second edition. Am J Clin Pathol. 1982; 77:123–36.Google Scholar
Bulbul Y, Oztuna F, Topba M, Ozlu T. Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis. Respiration. 2005;72:388–94.CrossRefPubMedGoogle Scholar
Würschmidt F, Bünemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys. 1995;33:77–82.PubMedGoogle Scholar
Tai P, et al. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer. 2007;7:31.CrossRefPubMedGoogle Scholar
Christodolou C, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res. 2002;22:3749–57.PubMedGoogle Scholar
Bremnes RM, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39:303–13.CrossRefPubMedGoogle Scholar
Sagman U, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol. 1991;9:1639–49.PubMedGoogle Scholar
Paesmans M, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523–33.CrossRefPubMedGoogle Scholar
Quoix E, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2000;30:127–34.CrossRefPubMedGoogle Scholar
Stokkel MP, van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol. 1998;124:215–9.CrossRefPubMedGoogle Scholar
Kristjansen PE, Osterlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer. 1986;58:2538–41.CrossRefPubMedGoogle Scholar